SpineGuard Reports Annual Revenue Growth for 2024
SpineGuard (FR0011464452 – ALSGD), a pioneering company utilizing its Dynamic Surgical Guidance (DSG) technology, has announced its full-year revenue results for 2024. This innovative technology helps in the accurate placement of bone implants and has seen a commendable performance this year.
Key Highlights from SpineGuard’s 2024 Financials
Pierre Jérôme, the Chairman and CEO of SpineGuard, shared insights on the company’s recovery following a rigorous 2023. After experiencing the exit of two key commercial agreements, the company returned to a growth trajectory in 2024, recording a significant 20% rise in revenue within the United States, which remains the largest market in the orthopedic sector.
Revenue Breakdown by Quarter
According to the reports, throughout 2024, SpineGuard's sales across various quarters highlighted steady growth:
- First Quarter: €1,351,000 compared to €1,271,000 in 2023 (+6%)
- Second Quarter: €1,095,000 compared to €963,000 in 2023 (+14%)
- Third Quarter: €1,174,000 compared to €978,000 in 2023 (+20%)
- Fourth Quarter: €1,028,000, showing a decline from €1,102,000 in 2023 (-7%)
The overall revenue for the year reached €4,648,000, marking an 8% increase compared to the previous year’s €4,313,000.
Sales Growth and Challenges
The rise in U.S. sales was propelled by numerous factors, including substantial orders from Omnia Medical and positive market responses following the formation of a new American sales team. In Europe, several countries, particularly Greece, Slovakia, Germany, and the Netherlands, contributed to a 4% growth, while the Middle East experienced a robust increase of 19%.
However, Latin America and Asia faced hurdles, with declines of 12% and 64% respectively. The issues in Asia were particularly attributed to ongoing challenges faced by XinRong Medical, SpineGuard's distributor in China, amidst the Chinese market’s regulatory environment. Yet, with upcoming product approvals anticipated from the National Medical Products Administration (NMPA) in 2025, there is optimism for recovery in that region.
Looking Towards 2025
As SpineGuard gears up for 2025, the focus remains on maintaining sales momentum through the launch of innovative products. The Threaded PediGuard, intended for scoliosis correction, and the PsiFGuard device co-developed with Omnia Medical for sacroiliac fusion represent significant milestones. Strengthening financial feet and building strategic partnerships are among SpineGuard’s priorities as they prepare for new challenges in the market.
Technological Innovations
The technological advancements spearheaded by SpineGuard are noteworthy. The company has paved the way for further applications of its DSG technology in areas such as dental implantology and surgical robotics. As a vital part of its expansion, SpineGuard remains engaged in multiple ESG initiatives and is committed to enhancing its sustainability efforts.
About SpineGuard
Established in 2009 by Pierre Jérôme and Stéphane Bette, SpineGuard has engaged in numerous surgical interventions leveraging its radiation-free real-time sensing technology. With over 100,000 surgeries supported globally and multiple peer-reviewed studies backing its effectiveness, SpineGuard continues to shape the future of surgical procedures.
Frequently Asked Questions
What is SpineGuard's primary product?
SpineGuard primarily offers the Dynamic Surgical Guidance (DSG) technology, which aids in the precise placement of bone implants.
How much did SpineGuard's revenue grow in 2024?
SpineGuard's revenue increased by 8% in 2024 compared to the previous year.
What markets contributed to SpineGuard's growth?
The United States saw a 20% growth, with additional contributions from Europe and the Middle East.
What challenges did SpineGuard face in Asia?
SpineGuard encountered a 64% decline in Asia due to difficulties experienced by its distributor, XinRong Medical, in the competitive market.
What future products does SpineGuard plan to launch?
SpineGuard is looking forward to launching the Threaded PediGuard and PsiFGuard, co-developed with Omnia Medical for enhancing surgical procedures.
